XVIPY OTC
Xvivo Perfusion AB (publ)
1W: -13.2%
1M: -29.1%
YTD: -15.9%
$5.50
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$822M
+37.6% ▲
5Y CAGR: +30.1%
Gross Profit
$616M
+38.5% ▲
5Y CAGR: +30.5%
Operating Income
$88M
+2010.2% ▲
5Y CAGR: +73.4%
Net Income
$172M
+87.5% ▲
5Y CAGR: +103.5%
EPS (Diluted)
$1.36
+77.2% ▲
5Y CAGR: +97.7%
EBITDA
$111M
-35.5% ▼
5Y CAGR: +45.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $180M | $258M | $415M | $598M | $822M |
| YoY Growth | -18.6% | +43.7% | +60.7% | +43.9% | +37.6% |
| Cost of Revenue | $47M | $70M | $118M | $152M | $206M |
| Gross Profit | $133M | $188M | $297M | $445M | $616M |
| Gross Margin | 73.9% | 72.9% | 71.5% | 74.5% | 75.0% |
| R&D Expenses | $56M | $54M | $69M | $136M | $148M |
| SG&A Expenses | $90M | $153M | $223M | $309M | $380M |
| Operating Expenses | $167M | $207M | $293M | $441M | $528M |
| Operating Income | -$34M | $7M | $23M | $4M | $88M |
| Operating Margin | -19.1% | 2.7% | 5.6% | 0.7% | 10.7% |
| Interest Expense | $361K | $276K | $605K | -$72M | $0 |
| Income Before Tax | -$57M | $7M | $22M | $95M | $200M |
| Tax Expense | -$14M | -$1M | $4M | $3M | $28M |
| Net Income | -$44M | $8M | $18M | $92M | $172M |
| Net Margin | -24.3% | 3.2% | 4.4% | 15.4% | 20.9% |
| EPS (Diluted) | $-0.40 | $0.07 | $0.16 | $0.77 | $1.36 |
| EBITDA | -$43M | $39M | $39M | $172M | $111M |
| Shares Outstanding | 109M | 116M | 118M | 120M | 127M |